Letosteine

TargetMol
Product Code: TAR-T60522
Supplier: TargetMol
CodeSizePrice
TAR-T60522-5mg5mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T60522-1mL1 mL * 10 mM (in DMSO)£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T60522-10mg10mg£131.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T60522-25mg25mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T60522-50mg50mg£225.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T60522-100mg100mg£301.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T60522-200mg200mg£417.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T60522-500mg500mg£643.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
Letosteine is an orally active, effective, and safe expectorant that can be used in the study of acute or chronic respiratory diseases, for example, bronchopulmonary disease. Letosteine dissolves bronchial mucus and reduces symptoms of respiratory inflammation and restores gas exchanges and natural defense mechanisms in the lung[1] [2] [3].
CAS:
53943-88-7
Molecular Weight:
279.38
Purity:
0.9603
SMILES:
O=C(OCC)CSCCC1SCC(N1)C(=O)O

References

Gachon F, et al. Disposition and metabolism of letosteine in rats. Drug Metab Dispos. 1988;16(6):853-857. Jia L. Letosteine. John Wiley & Sons, Ltd, 2014. Zhou Y, et al. Efficacy and safety of letosteine in the treatment of sputum thickening and expectoration difficulty in patients with respiratory diseases: a multicenter, randomized, double-masked, double dummy, positive drug parallel controlled trial. Pharmazie. 2014 Nov;69(11):842-9. Macquet V, et al. A new contribution to the treatment of chronic bronchopneumopathies: letosteine. Lille Med. 1979;24(9):735-738.